Caleb Bozeman, MD
Urology · Little Rock, ARNPI 1881669513
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $111,000 of the $135,676 with a category attached, or 81.8%. Cryo Specialty Medical, LLC accounts for 91.8% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $39,038 and has fallen 96.7% since, to $1,286 in 2025. Among urology clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 538 payments — averaging $252.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cryo Specialty Medical, LLC$125K
- Coloplast$3K
- Boston Scientific$1K
- Sumitomo Pharma America, Inc.$727
- Astellas Pharma US Inc$709
- AbbVie$522
- plus $5K from 34 others
What the payments were for
- Speaking & faculty fees$13,50010%
- Travel & lodging$5850%
- Food & beverage$10,5768%
- Education$150%
- Ownership interest$111,00082%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cryo Specialty Medical, LLC | 5 | $124,500 |
| Coloplast | 166 | $3,378 |
| Boston Scientific | 13 | $1,072 |
| Sumitomo Pharma America, Inc. | 39 | $727 |
| Astellas Pharma US Inc | 50 | $709 |
| AbbVie(2 entities) | 32 | $522 |
| Teleflex LLC | 8 | $516 |
| Axonics, Inc. | 27 | $511 |
| Pfizer | 28 | $472 |
| Myovant Sciences Inc. | 14 | $329 |
| Dendreon Pharmaceuticals LLC | 17 | $329 |
| Myriad Genetic Laboratories, Inc. | 6 | $324 |
| Blue Earth Diagnostics | 14 | $271 |
| Tolmar, Inc. | 15 | $239 |
| Johnson & Johnson | 11 | $194 |
| Medtronic(2 entities) | 20 | $192 |
| Neotract Inc. | 9 | $188 |
| Endo Pharmaceuticals Inc. | 11 | $174 |
| Bayer | 8 | $137 |
| Antares Pharma, Inc. | 7 | $131 |
| Urogen Pharma, Inc. | 4 | $85 |
| Amgen | 4 | $76 |
| Caris MPI, Inc. | 3 | $67 |
| Merck | 3 | $64 |
| Procept Biorobotics Corporation | 2 | $59 |
| Ferring Pharmaceuticals Inc. | 2 | $50 |
| Verity Pharmaceuticals Inc. | 2 | $39 |
| AstraZeneca | 2 | $38 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $37 |
| Endo USA, Inc. | 2 | $36 |
| Novartis | 2 | $34 |
| Urovant Sciences Inc | 2 | $31 |
| Tolmar Pharmaceuticals, Inc. | 1 | $24 |
| Angiodynamics, Inc. | 1 | $22 |
| Travere Therapeutics, Inc. | 1 | $19 |
| Immunitybio, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $17 |
| Cure Medical LLC | 1 | $17 |
| Halozyme Inc | 1 | $16 |
| Civco Medical Instruments | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$135,676 in reported general payments places this provider in the 95th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 39 | $672,572 |
| NubeqaDarolutamide | 11 | $150,884 |
| OrgovyxRelugolix | 46 | $119,728 |
| MyrbetriqMirabegron | 158 | $93,078 |
| GemtesaVibegron | 102 | $59,072 |
| Tamsulosin Hcl | 1,121 | $10,900 |
| Fosfomycin Tromethamine | 16 | $7,388 |
| Testosterone Cypionate | 238 | $6,744 |
| Abiraterone Acetate | 15 | $5,915 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 155 | $5,068 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 20 | $3,842 |
| Finasteride | 303 | $2,634 |
| Dutasteride | 113 | $2,437 |
| Ciprofloxacin Hcl | 229 | $1,261 |
| Tolterodine Tartrate ErTolterodine Tartrate | 22 | $1,114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $709 | $765,650197 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $727 | $178,800148 claims |
| BayerNubeqa | $137 | $150,88411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 88 urology providers in Arkansas.
Other urology in Little Rock
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- David CoussensLittle Rock$134K
- Timothy LangfordLittle Rock$133K
- Kevin ClaybrookLittle Rock$132K
- Gail JonesLittle Rock$128K
- John MooreLittle Rock$19K
- Michael ChildsLittle Rock$8K
- Bruno Lopes Cancado MachadoLittle Rock$7K
- Marcelo BigarellaLittle Rock$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.